We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$2B
1-Year Est. Return
147.21%
This Fund
S&P 500
This Quarter
Est. Return
+60.74%
1 Year Est. Return
+147.21%
3 Year Est. Return
+369.71%
5 Year Est. Return
+164.99%
10 Year Est. Return
+6,568.53%
AUM
$1.09B
AUM Growth
+$121M
(+13%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-9.9%
Top 10 Holdings %
Top 10 Hldgs %
62.33%
Holding
35
New
2
Increased
10
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$30M |
| 2 |
Denali Therapeutics
DNLI
|
+$9.99M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$7.37M |
| 4 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$6.2M |
| 5 |
CareDx
CDNA
|
+$4.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$83.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$21.2M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$20.9M |
| 4 |
Q32 Bio
QTTB
|
+$14.8M |
| 5 |
Editas Medicine
EDIT
|
+$9.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.39% |
| 2 | Miscellaneous | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$2.18B
| $86.5M | 7.95% |
670,000
-210,000
| -24% | -$21.2M |
|
|
BLUE
2
DELISTED
bluebird bio
BLUE
| $85.1M | 7.83% |
74,884
+27,599
| +58% | +$30M |
|
3
Codexis
CDXS
$145M
| $81.1M | 7.46% |
5,073,780
| – | – |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $75.3M | 6.92% |
940,000
| – | – |
|
|
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $73.2M | 6.74% |
1,005,000
-110,000
| -10% | -$6.67M |
|
6
Alnylam Pharmaceuticals
ALNY
$32.9B
| $59.3M | 5.45% |
515,000
-85,000
| -14% | -$8.47M |
|
|
NVTA
7
DELISTED
Invitae Corporation
NVTA
| $58.7M | 5.4% |
3,638,388
-200,000
| -5% | -$3.54M |
|
|
CNST
8
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $57.1M | 5.25% |
1,212,734
-311,226
| -20% | -$8.99M |
|
|
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
| $51.5M | 4.73% |
860,000
| – | – |
|
10
Fate Therapeutics
FATE
$302M
| $49.9M | 4.59% |
2,550,000
| – | – |
|
11
Dianthus Therapeutics
DNTH
$5.66B
| $47M | 4.32% |
193,633
+3,125
| +2% | +$584K |
|
12
BioLife Solutions
BLFS
$1.8B
| $39.9M | 3.67% |
2,468,571
+40,000
| +2% | +$650K |
|
13
Agios Pharmaceuticals
AGIO
$2.01B
| $39.4M | 3.62% |
825,000
-110,000
| -12% | -$4.16M |
|
|
14
CareDx
CDNA
$2.81B
| $25.9M | 2.38% |
1,200,000
+200,000
| +20% | +$4.59M |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $23.8M | 2.19% |
300,000
| – | – |
|
|
16
Denali Therapeutics
DNLI
$3.22B
| $21.8M | 2% |
1,250,000
+600,000
| +92% | +$9.99M |
|
17
Fulcrum Therapeutics
FULC
$288M
| $20.6M | 1.9% |
1,239,285
+395,000
| +47% | +$3.78M |
|
18
Illumina
ILMN
$37B
| $19.9M | 1.83% |
61,680
| – | – |
|
|
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $19.4M | 1.78% |
2,160,000
+390,000
| +22% | +$3.25M |
|
20
Alector
ALEC
$207M
| $18.5M | 1.71% |
1,076,039
+265,000
| +33% | +$4.5M |
|
|
SAGE
21
DELISTED
Sage Therapeutics
SAGE
| $16.6M | 1.53% |
230,000
-170,000
| -43% | -$20.9M |
|
|
GNMK
22
DELISTED
GenMark Diagnostics, Inc
GNMK
| $16.2M | 1.49% |
3,365,000
| – | – |
|
|
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $15.9M | 1.46% |
255,000
+155,000
| +155% | +$7.37M |
|
24
Voyager Therapeutics
VYGR
$187M
| $15.3M | 1.4% |
1,095,075
-33,000
| -3% | -$480K |
|
25
Adaptive Biotechnologies
ADPT
$4.56B
| $13.9M | 1.27% |
463,125
| – | – |
|
Similar funds
KOCAA
NL
CAM
SB
BGGS
CC
JWA
FOF
Casdin Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Casdin Capital held 35 positions worth $1.09B, up 13% from $966M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Casdin Capital withdrew a net $108M in Q4 2019, closing 3 positions and reducing 8 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $83.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Casdin Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $4.51M.
- Casdin Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 1,500,000 shares worth $4.51M.
- Casdin Capital added most to bluebird bio in Q4 2019, an estimated $30M increase.
- Casdin Capital's biggest Q4 2019 reduction was Sarepta Therapeutics, cutting an estimated $21.2M.
- Casdin Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $83.7M.
- Casdin Capital's ten largest holdings make up 62% of its $1.09B portfolio in Q4 2019.
- Casdin Capital opened 2 new positions and closed 3 in Q4 2019.
- Casdin Capital's portfolio value rose 13% quarter-over-quarter to $1.09B.
Based on Casdin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.